Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vi capsular polysaccharide vaccine (Vi-PS) is a subunit vaccine used to prevent typhoid fever. It contains purified Vi polysaccharide extracted from Salmonella enterica serovar Typhi. Each 0.5 mL dose contains 25 mcg of purified Vi polysaccharide in a phosphate buffered saline solution. The vaccine induces a T cell-independent B cell response and provides protection for approximately 2 years, with an efficacy of about 55% in older children and adults. It is administered as an intramuscular injection and is indicated for use in individuals 2 years of age and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vi capsular polysaccharide vaccine.